Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK14 | Q16539 | 20/20 | 1.00 |
| ▸ | MAPK13 | O15264 | 1/20 | 1.00 |
| ▸ | HSPB1 | P04792 | 1/20 | 1.00 |
| ▸ | HTR2A | P28223 | 1/20 | 1.00 |
| ▸ | HTR2B | P41595 | 1/20 | 1.00 |
| ▸ | MAPK12 | P53778 | 1/20 | 1.00 |
| ▸ | MAPK11 | Q15759 | 1/20 | 1.00 |
| ▸ | TMEM97 | Q5BJF2 | 1/20 | 1.00 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Skepinone-L SCHEMBL20877164 | 1.00 | MAPK14 (1.00) | MAPK14MAPK13HSPB1HTR2AHTR2B | |
| Skepinone-L SCHEMBL29527315 | 1.00 | MAPK14 (1.00) | MAPK14MAPK13HSPB1HTR2AHTR2B | |
| Skepinone-L SCHEMBL2685836 | 1.00 | MAPK14 (1.00) | MAPK14MAPK13HSPB1HTR2AHTR2B | |
| Skepinone-L SCHEMBL30197623 | 1.00 | MAPK14 (1.00) | MAPK14MAPK13HSPB1HTR2AHTR2B | |
| SCHEMBL4399789 | 0.96 | MAPK14 (1.00) | MAPK14MAPK13HSPB1HTR2AHTR2B | |
| SCHEMBL30336051 | 0.96 | MAPK14 (1.00) | MAPK14MAPK13HSPB1HTR2AHTR2B | |
| SCHEMBL2317837 | 0.96 | MAPK14 (1.00) | MAPK14MAPK13HSPB1HTR2AHTR2B | |
| SCHEMBL2315888 | 0.91 | MAPK14 (1.00) | MAPK14MAPK13HSPB1HTR2AHTR2B | |
| SCHEMBL2318032 | 0.87 | MAPK14 (1.00) | MAPK14MAPK13HSPB1HTR2AHTR2B | |
| SCHEMBL2320212 | 0.86 | MAPK14 (1.00) | MAPK14MAPK13HSPB1HTR2AHTR2B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 146 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4720261-A1 | NOVEL CULTURE CONDITIONS FOR CLONAL EXPANSION OF NEPHRON PROGENITOR CELLS, GENERATION OF NEPHRON ORGANOIDS, AND RAPID AND SCALABLE MODELING OF POLYCYSTIC KIDNEY DISEASE | University of Southern California (US) | 2026-04-08 | — | — | EP | claimed |
| EP-4615506-A1 | USE OF GSK-3 ACTIVATIOR TO MODULATE PROTEASOME ACTIVITY TO PREVENT AGEING ASSOCIATED CONDITIONS AND DISEASES | Sahin, Fikret (TR) | 2025-09-17 | — | — | EP | claimed |
| WO-2024258363-A1 | USE OF GSK-3 ACTIVATIOR TO MODULATE PROTEASOME ACTIVITY TO PREVENT AGEING ASSOCIATED CONDITIONS AND DISEASES | SAHIN FIKRET (TR) | 2024-12-19 | — | — | WO | claimed |
| WO-2024243567-A1 | NOVEL CULTURE CONDITIONS FOR CLONAL EXPANSION OF NEPHRON PROGENITOR CELLS, GENERATION OF NEPHRON ORGANOIDS, AND RAPID AND SCALABLE MODELING OF POLYCYSTIC KIDNEY DISEASE | UNIVERSITY OF SOUTHERN CALIFORNIA (US) | 2024-11-28 | — | — | WO | claimed |
| WO-2024189434-A1 | USE OF NADOLOL TO TREAT PULMONARY SYMPTOMS ASSOCIATED WITH INFECTIONS WITH SARS-CoV-2 | CHRONIC AIRWAY THERAPEUTICS LIMITED (AU) | 2024-09-19 | — | — | WO | claimed |
| US-20240156816-A1 | METHODS AND COMPOSITIONS FOR PREDICTING AND PREVENTING RELAPSE OF ACUTE LYMPHOBLASTIC LEUKEMIA | DANA-FARBER CANCER INSTITUTE, INC. | 2024-05-16 | — | — | US | claimed |
| US-11844800-B2 | Methods and compositions for predicting and preventing relapse of acute lymphoblastic leukemia | MASSACHUSETTS INSTITUTE OF TECHNOLOGY (US) | 2023-12-19 | — | — | US | claimed |
| WO-2023196235-A1 | METHODS, DEVICES, AND SYSTEMS FOR TREATING LENS PROTEIN AGGREGATION DISEASES | GLAZIER ALAN NEIL (US) | 2023-10-12 | — | — | WO | claimed |
| US-20230310471-A1 | METHODS, DEVICES, AND SYSTEMS FOR TREATING LENS PROTEIN AGGREGATION DISEASES | GLAZIER ALAN NEIL (US) | 2023-10-05 | — | — | US | claimed |
| US-20230190736-A1 | SMALL MOLECULE THERAPEUTICS FOR THE TREATMENT OF VIRAL INFECTIONS | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA | 2023-06-22 | — | — | US | claimed |
| EP-2349964-B1 | DIBENZOCYCLOHEPTANONE DERIVATIVES AND PHARMACEUTICAL AGENTS CONTAINING SAID COMPOUNDS | C A I R BIOSCIENCES GMBH (DE) | 2015-09-09 | — | — | EP | claimed |
| US-8633312-B2 | Dibenzocycloheptatone derivatives and pharmaceutical agents containing said compounds | C-A-I-R BIOSCIENCES GMBH (DE) | 2014-01-21 | — | — | US | claimed |
| US-20120115862-A1 | DIBENZOCYCLOHEPTATONE DERIVATIVES AND PHARMACEUTICAL AGENTS CONTAINING SAID COMPOUNDS | C-A-I-R BIOSCIENCES GMBH (DE) | 2012-05-10 | — | — | US | claimed |
| EP-2206534-A1 | Dibenzocycloheptanone derivatives und pharmaceutical agents containing these compounds | c-a-i-r biosciences GmbH (DE) | 2010-07-14 | — | — | EP | claimed |
| US-12599592-B2 | Therapeutic small molecules for treatment of pulmonary hypertension | UNIVERSITY OF PITTSBURGH-OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION (US) | 2026-04-14 | — | — | US | disclosed |
| EP-4720261-A1 | NOVEL CULTURE CONDITIONS FOR CLONAL EXPANSION OF NEPHRON PROGENITOR CELLS, GENERATION OF NEPHRON ORGANOIDS, AND RAPID AND SCALABLE MODELING OF POLYCYSTIC KIDNEY DISEASE | University of Southern California (US) | 2026-04-08 | — | — | EP | disclosed |
| CN-120899683-A | Use of Skepinone-L for killing neuroblastoma cells | 大连市妇女儿童医疗中心(集团) | 2025-11-07 | — | — | CN | disclosed |
| US-20150056604-A1 | COMPOSITIONS AND METHODS FOR PRESERVING PLATELET FUNCTION | BIOVEC TRANSFUSION, LLC | 2015-02-26 | — | — | US | disclosed |
| US-8633312-B2 | Dibenzocycloheptatone derivatives and pharmaceutical agents containing said compounds | C-A-I-R BIOSCIENCES GMBH (DE) | 2014-01-21 | — | — | US | disclosed |
| US-20120115862-A1 | DIBENZOCYCLOHEPTATONE DERIVATIVES AND PHARMACEUTICAL AGENTS CONTAINING SAID COMPOUNDS | C-A-I-R BIOSCIENCES GMBH (DE) | 2012-05-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12599592-B2 | Therapeutic small molecules for treatment of pulmonary hypertension | GSTP1, GSTK1, GSTM1 | MAPK14 2659/4885MAPK13 3460/4885HSPB1 70/4885 |
| US-20120115862-A1 | DIBENZOCYCLOHEPTATONE DERIVATIVES AND PHARMACEUTICAL AGENTS CONTAINING SAID COMPOUNDS | IL1B, NFKBIA, IL1R1 | MAPK14 2812/4885MAPK13 2654/4885HSPB1 899/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.